Abstract: Compounds of formula I
are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
Type:
Grant
Filed:
November 19, 1999
Date of Patent:
August 14, 2001
Assignee:
Abbott Laboratories
Inventors:
Mark W. Holladay, William A. Carroll, Irene Drizin, Lin Yi, Henry Q. Zhang
Abstract: Compounds having the formula
are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
Type:
Grant
Filed:
December 4, 1998
Date of Patent:
July 24, 2001
Assignee:
Abbott Laboratories
Inventors:
William A. Carroll, Irene Drizin, Mark W. Holladay, James P. Sullivan, Henry Q. Zhang
Abstract:
The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.
Type:
Grant
Filed:
October 20, 1999
Date of Patent:
February 20, 2001
Assignee:
Abbott Laboratories
Inventors:
William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
Abstract: Compounds of Formula I and II and their pharmaceutically acceptable, salts, esters and prodrugs thereof are selective alpha-1D adrenoceptor anatagonists and may be useful for treating disease states.
Abstract: Compounds of Formula I ##STR1## and II and their pharmaceutically acceptable, salts, esters and prodrugs thereof are selective alpha-1D adrenoceptor anatagonists and may be useful for treating disease states, such as benign prostatic hyperplasia, detrusor insatbility, and incontinence.
Abstract: Compounds having the formula are .alpha..sub.1 adrenoreceptor antagonists. Processes for making these compounds, synthetic intermediates employed in these processes and a method for inhibiting .alpha..sub.1 adrenoreceptors and treating benign prostatic hyperplasia (also called benign prostatic hypertrophy or BPH) and other urological diseases such as BOO (bladder outlet obstruction), neurogenic bladder and gynecological syndromes such as dysmenorrhea are disclosed.
Type:
Grant
Filed:
May 6, 1998
Date of Patent:
October 17, 2000
Assignee:
Abbott Laboratories
Inventors:
Paul P. Ehrlich, Jeffrey W. Ralston, Jerome F. Daanen, Michael D. Meyer
Abstract: The process of the present invention relates to a process for producing 1 3-cis retinoic acid. The process of the present invention involves reacting a Wittig salt in a solvent with a butenolide in the presence of a weak base and a Lewis acid.
Type:
Grant
Filed:
March 25, 1998
Date of Patent:
September 26, 2000
Assignee:
Abbott Laboratories
Inventors:
Xiu C. Wang, Ashok V. Bhatia, Azad Hossain, Timothy B. Towne
Abstract: A process for preparing chiral isomers of N-protected 2-azetidinemethanol compounds, particularly N-(phenylmethyl)-2-azetidinemethanol and N-BOC-2-azetidinemethanol, and especially the (R)-isomers thereof, as well as O-substituted derivatives thereof.
Type:
Grant
Filed:
December 21, 1999
Date of Patent:
September 26, 2000
Assignee:
Abbott Laboratories
Inventors:
Anthony R. Haight, John E. Lallaman, Gregory S. Wayne
Abstract: The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 adrenoreceptors and treating BPH.
Type:
Grant
Filed:
November 26, 1997
Date of Patent:
April 4, 2000
Inventors:
Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, James F. Kerwin, Jr., Michael D. Wendt, Anthony R. Haight, Weijiang Zhang
Abstract: Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.
Type:
Grant
Filed:
April 11, 1997
Date of Patent:
December 14, 1999
Assignee:
Abbott Laboratories
Inventors:
Richard L. Elliott, Keith B. Ryther, Mark W. Holladay, James T. Wasicak, Jerome F. Daanen, Nan-Horng Lin, Michael J. Dart, Yun He, Yihong Li
Abstract: The present invention relates to pesticidal compositions comprising an amount of a UV sensitive pesticide and a lignin as a UV sunscreen in an effective amount to protect the pesticide against inactivation by UV radiation for extending the persistence of the UV sensitive pesticide in the natural environment to control a pest and/or for reducing the amount of the pesticide typically needed to be a commercially effective pesticide. The present invention also relates to a method for protecting a UV sensitive pesticide against inactivation by UV radiation. The present invention further relates to a method for controlling a pest comprising exposing the pest to the pesticidal compositions of the present invention.
Type:
Grant
Filed:
October 22, 1996
Date of Patent:
November 30, 1999
Assignee:
Abott Laboratories
Inventors:
David G. Hobbs, Brian J. Campbell, William D. Lidster
Abstract: The invention is related to a novel strain(s) of Bacillus thuringiensis in which essentially all of the pesticidal activity of said strain is in the supernatant of a fermentation of said strain. The strain produces a substance which has activity against an insect pest(s) of the order Coleoptera and which enhances the pesticidal activity of a Bacillus related pesticide. The invention further relates to pesticidal compositions comprising the substance and a pesticidal carrier, or the substance and a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties as well as methods of using the pesticidal compositions to control a pest.
Type:
Grant
Filed:
October 8, 1997
Date of Patent:
November 2, 1999
Assignee:
Abbott Laboratories
Inventors:
Chi-Li Liu, Anita M. MacMullan, Patricia Ann Lufburrow, Robert L. Starnes, Denise C. Manker
Abstract: The invention is related to a novel strain(s) of Bacillus thuringiensis in which essentially all of the pesticidal activity of said strain is in the supernatant of a fermentation of said strain. The strain produces a substance which has activity against an insect pest(s) of the order Coleoptera and which enhances the pesticidal activity of a Bacillus related pesticide. The invention further relates to pesticidal compositions comprising the substance and a pesticidal carrier, or the substance and a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties as well as methods of using the pesticidal compositions to control a pest.
Type:
Grant
Filed:
October 8, 1997
Date of Patent:
November 2, 1999
Assignee:
Abbott Laboratories
Inventors:
Chi-Li Liu, Anita M. MacMullan, Patricia Ann Lufburrow, Robert L. Starnes, Denise C. Manker
Abstract: The invention relates to a method for producing an integrant(s) of Bacillus thuringiensis. The invention further relates to such integrants, compositions comprising such integrants, as well as methods for controlling a pest(s) using these compositions.
Type:
Grant
Filed:
April 14, 1998
Date of Patent:
September 21, 1999
Assignee:
Abbott Laboratories
Inventors:
Lee Fremont Adams, Michael David Thomas, Alan P. Sloma, William R. Widner, Steen Troels J.o slashed.rgensen, Per Lin.ang. J.o slashed.rgensen, B.o slashed.rge Krag Diderichsen
Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 7, 1999
Assignee:
Abbott Laboratories
Inventors:
Melwyn A. Abreo, David E. Gunn, Nan-Horng Lin, David S. Garvey, Mark W. Holladay, Keith B. Ryther
Abstract: A solid phase synthesis method and intermediates useful in the process are disclosed for the preparation of diamino diol and diamino alcohol inhibitors of HIV protease.